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Abstract The novel inhibitor 7-N-phenylcarbamoylamino-4-
chloro-3-propyloxyisocoumarin (ICD 1578) was tested for its
ability to antagonize the zinc metalloprotease activity of
botulinum toxin B (BoNT/B). The efficacy of this compound
was tested in a cell-free system using a 50-mer synaptobrevin
peptide as substrate. The peptide, designated as [Pya88] S 39^88,
had a fluorescent amino acid analog, L-pyrenylalanine (Pya),
substituted for the normal Phe88 of synaptobrevin-2. Cleavage by
BoNT light chain yielded fragments of 38 and 11 amino acids,
respectively. The smaller fragment, containing the Pya fluo-
rophore, was readily separated and quantified by fluorescence
spectroscopy at 377 nm. In the presence of 7^200 WM ICD 1578,
cleavage of [Pya88] S 39^88 was progressively reduced
(IC50 = 27.6 WM), and 100 WM ICD 1578 produced s95%
inhibition. For comparison, captopril, a well-known zinc
metalloprotease inhibitor, generated less than 10% inhibition at
a concentration of 5 mM. ICD 1578 is the most potent
antagonist of BoNT/B light chain thus far described.
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1. Introduction
Botulinum neurotoxin (BoNT) inhibits acetylcholine release
from motor nerve terminals resulting in a £accid paralysis of
skeletal muscle [1]. The paralytic action of BoNT leads to a
characteristic set of symptoms which generally include diplo-
pia, dysphagia, generalized muscle weakness, muscle paralysis
and death [1,2]. Each of the seven serotypes of BoNT consists
of a light chain (LC) of V50 kDa that has zinc metallopro-
tease activity and cleaves one of three proteins associated with
transmitter release: synaptobrevin, SNAP-25 or syntaxin. The
LC is linked by a single disul¢de bond and noncovalent forces
to a heavy chain of V100 kDa that is responsible for the
binding of the toxin to the nerve terminal and for internal-
ization of the LC into the cytosol [1^3].
BoNT is a potential military threat and a signi¢cant public
health problem [4]. Our current treatment of BoNT intoxica-
tion is largely symptomatic, directed at maintaining respira-
tory and cardiovascular function [5]. Since botulism leads to
protracted paralysis with long-lasting consequences, it is im-
portant to develop e¡ective pharmacological treatments for
BoNT toxicity.
There are three potential targets for antagonism of BoNT
action: the ectoacceptor on the surface of cholinergic nerve
terminals, the exocytotic apparatus that mediates toxin inter-
nalization and the active site of the LC [2,6]. Blockade of the
ectoacceptor has proved di⁄cult, since this moiety is poorly
characterized [1,2,7]. Inhibition of internalization has met
with greater success, however, the agents thus far examined
have only delayed but could not prevent muscle paralysis [8^
10]. Attempts to inhibit the active site of the BoNT LC have
been con¢ned to the use of zinc chelators and the metallopro-
tease inhibitors, captopril and phosphoramidon. The chelators
were found to be e¡ective in vitro but highly toxic in vivo
[11,12], while the available metalloprotease inhibitors were
only marginally e¡ective even under in vitro conditions
[6,13,14]. The latter is not surprising, since these inhibitors
are not optimized to interact with the active sites of the clos-
tridial neurotoxin LCs.
The present e¡ort represents a rational approach towards
the use of selective metalloprotease inhibitors for BoNT/B; a
task that is rendered di⁄cult by the absence of X-ray crystal-
lographic data on this BoNT serotype and by the lack
of e¡ective lead compounds. The inhibitor 7-N-phenylcar-
bamoylamino-4-chloro-3-propyloxyisocoumarin (ICD 1578)
was originally designed to interact with matrix metallopro-
teases. For the current investigation, ICD 1578 was selected
as a potential BoNT/B LC inhibitor since it shared structural
similarities with a weakly active phosphoramidon analog [15].
ICD 1578 was assessed for its ability to inhibit the catalytic
activity of BoNT/B LC using a sensitive £uorescence assay.
The results indicate that ICD 1578 is the most potent inhib-
itor of BoNT/B thus far examined.
2. Materials and methods
2.1. Fluorescence assay
A quantitative £uorescent assay was used for evaluating the e⁄cacy
of BoNT/B LC inhibitors. The assay is based on monitoring reduc-
tions in the rate of cleavage of a 50-mer peptide that spans residues 39
to 87 of human synaptobrevin-2 and contains a modi¢ed tyrosine
(pyrenylalanine) £uorophore in position 88 that is normally occupied
by phenylalanine. This substrate, designated as [Pya88] S 39^88, was
described in detail by Soleihac et al. [16].
The assay was carried out at 22‡C in a reaction volume of 100 Wl.
Due to the light sensitivity of the pyrenylalanine £uorophore, all
operations were performed with subdued incandescent lighting. First,
60 nM of pure BoNT/B LC was preincubated with 50 WM ZnSO4,
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1 mM dithiothreitol and 20 mM HEPES (pH 7.1) for 30 min. This
was followed by a 30 min incubation with 10 WM of the substrate
[Pya88] S 39^88. The reaction was stopped after 30 min by addition of
0.9 ml of 0.1% tri£uoroacetic acid (TFA) in 72% methanol. The re-
action blank consisted of equivalent concentrations of HEPES and
[Pya88] S 39^88 but without BoNT LC, dithiothreitol or added
ZnSO4. Stock solutions of the inhibitors ICD 1578 or captopril
were prepared in 20 mM HEPES (adjusted to pH 7.1) and added to
the preincubation mixture.
During incubation, BoNT/B LC cleaves the peptide bond between
Gln76 and Phe77, resulting in two fragments: a 38-mer peptide (S 39^
76) and a smaller 12-mer peptide ([Pya88] S 77^88) that contains the
pyrenylalanine £uorophore. Isolation of the latter was accomplished
by using C18 Sep-Pak Vac syringe body cartridges (Waters Corp.,
Milford, MA). The C18 matrix retains the hydrophobic parent pep-
tide and larger S 39^76 cleavage product while eluting the hydrophilic
[Pya88] S 77^88 fragment [16]. Sep-Pak cartridges were mounted on a
Baker-10 (Phillipsburg, NJ) solid phase extraction vacuum manifold
equipped with stopcock valves to control £ow through individual
cartridges. Prior to separation, cartridges were conditioned by three
5 ml washes containing, respectively, 0.1% TFA in methanol, pure
methanol and 0.1% TFA in 65% methanol: these solutions were sub-
sequently discarded. To achieve separation, 1 ml sample volumes con-
taining reaction products and uncleaved substrate were loaded on
cartridges, and the hydrophilic C-terminal peptide fragment was
eluted through the C18 matrix at V1 ml per min. Cartridges were
then washed with 3 ml of 0.1% TFA in 65% methanol to remove
residual [Pya88] S 77^88 cleavage product. The eluate and 2 ml of
the ¢nal wash solution were collected and used for £uorometric anal-
ysis.
For quantitative determinations, the [Pya88] S 77^88-containing sol-
ution was transferred to a quartz cuvette, and monitored for £uores-
cence using a Spex Fluoromax (Edison, NJ) with a 90‡ £uorescence
cell. The excitation wavelength was set to 353 nm (5 nm slit) and
emission wavelength was adjusted to scan between 360^460 nm (7
nm slit). Fractional inhibition was calculated at 377 nm using the
formula 13(I3B)/(C3B), where I, B and C are emissions for inhib-
ited, blank and control samples, respectively.
2.2. Molecular modeling
Models of ICD 1578 were constructed using Insight II software and
simulated under the ‘electrostatic force ¢eld’ using Discover software
on a Silicon Graphics computer. The ICD 1578 molecule was placed
in a solvent cell with periodic boundary conditions. Explicit water
molecules were then added to the unit cell to approximate a solvated
molecule. After energy minimization, 15 000 time steps of dynamics
with a step size of 1 fs were performed. An average structure was then
deduced by examining the trajectory ¢les and averaging bond lengths
and rotation angles after the structures appeared to have stabilized.
2.3. Materials
ICD 1578 (Fig. 1) was designed and synthesized by Dr. James
Powers (Georgia Institute of Technology, Atlanta, GA) under con-
tract to the Department of the Army. Pure BoNT/B LC was obtained
from Drs. Eric Johnson and Michael Goodnough (Food Research
Institute, Madison, WI). [Pya88] S 39^88 was a generous gift from
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Fig. 1. Molecular structure of ICD 1578. A is a conventional structural diagram; B shows a wall-eyed stereo view of an energy minimized
structure. The molecular weight of ICD 1578 is 372.45. The identity and purity of the compound were con¢rmed by NMR analysis. Note that
ICD 1578 is predicted to be semi-rigid due to the fused isocoumarin ring and the limited degrees of rotational freedom between isocoumarin
and phenyl rings.
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Drs. Fabrice Cornille and Bernard Roques (UniversiteŁ Rene Des-
cartes, Paris, France). Methanol (optimal spectrophotometric grade)
was purchased form Fisher Scienti¢c Co. (Pittsburgh, PA). TFA (pep-
tide synthesis grade) was obtained from Millipore, Inc. (Bedford,
MA). Captopril, ultrapure ZnSO4 and HEPES were acquired from
Sigma-Aldrich Chemical Co. (St. Louis, MO). All other chemicals
were reagent grade or higher.
2.4. Statistical analysis
Concentration-response data were ¢t by a nonlinear regression pro-
gram (GraphPad Prism v 2.01, San Diego, CA). Statistical signi¢cance
was tested by a one-way ANOVA with Dunnett’s post tests.
3. Results
3.1. E¡ect of ICD 1578 on BoNT/B-mediated substrate
cleavage
Fluorescence spectra of the 12-mer [Pya88] S 77^88 cleavage
product in the absence and presence of ICD 1578 are illus-
trated in Fig. 2. The upper traces, labeled control, represent
cleavage of the substrate [Pya88] S 39^88 by the pure BoNT/B
LC prior to addition of inhibitor. Under this condition, £uo-
rescence signals were observed with peaks at 377 and 392 nm
corresponding to normal BoNT/B proteolytic activity. The
control spectra shown in Fig. 2 were obtained from two sep-
arate reactions and demonstrate the reproducibility of the
assay.
The e¡ect of potential inhibitors on this reaction was eval-
uated by pretreating the BoNT/B LC for 30 min with the
presumptive inhibitor prior to incubation of the BoNT/B
LC-inhibitor complex with [Pya88] S 39^88. In the presence
of ICD 1578, there was a marked and progressive decrease in
£uorescence intensity due to inhibition of BoNT/B-mediated
proteolysis.
Concentration-response data for ICD 1578 over the range
7^200 WM from 3^4 such experiments are shown in Fig. 3.
The lowest concentration of ICD 1578 examined was 7 WM,
which failed to inhibit the BoNT/B-mediated cleavage signi¢-
cantly. Higher concentrations of ICD 1578, however, pro-
duced a signi¢cant, concentration-dependent inhibition of
BoNT/B proteolysis, with nearly complete inhibition occur-
ring at 100 WM. From the sigmoid curve ¢tted to the data,
the IC50 was determined to be 27.6 WM. In the absence of
BoNT/B LC, ICD 1578 did not quench the £uorescence of
[Pya88] S 39^88, indicating that the decrease in £uorescence in
Figs. 2 and 3 was due to inhibition of BoNT/B LC.
3.2. E¡ects of captopril on BoNT/B-mediated cleavage of
[Pya88] S 39^88
Since ICD 1578 is a new protease inhibitor, it was of inter-
est to compare its activity with that of the well-characterized
metalloprotease inhibitor, captopril. Fluorescence spectra for
the inhibitory actions of captopril on BoNT-mediated cleav-
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Fig. 2. Representative £uorescence spectra of the 12-mer [Pya88] S 77^88 cleavage product in the absence or presence of ICD 1578. The spectra
represent £uorescence intensity in arbitrary units at the indicated wavelengths. The peak at 377 nm was used for quanti¢cation in conformity
with Soleihac et al. [16].
Fig. 3. Concentration-response curves for ICD 1578. The symbols
represent the mean þ S.E. of data obtained from 3^4 replicate sam-
ples. The curve was ¢t by a nonlinear regression analysis and
yielded an IC50 of 27.6 WM. All points v 20 WM were found to dif-
fer signi¢cantly from control using a one-way ANOVA with Dun-
nett’s post test (P6 0.01).
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age of [Pya88] S 39^88 are depicted in Fig. 4. Experiments
were performed in the absence of inhibitor and 30 min after
preincubation of BoNT/B LC with 5 mM captopril. Even at
this very high concentration, captopril produced only a mar-
ginal inhibition of BoNT/B activity. These results con¢rm
those obtained earlier using a recombinant synaptobrevin pep-
tide as substrate [14].
4. Discussion
The results of this investigation indicate that ICD 1578 is a
potent antagonist of BoNT/B LC, and the ¢rst organic inhib-
itor for this site that is e¡ective in the sub-millimolar range;
ICD 1578 was able to inhibit the proteolytic activity of BoNT/
B with an IC506 30 WM. Previous investigators have sug-
gested that captopril, a widely prescribed antihypertensive
agent, may be useful for treatment of BoNT/B intoxication
[17]. Although captopril is e¡ective in inhibiting angiotensin
converting enzyme, its intended target, it had little e⁄cacy in
antagonizing BoNT in either cell-free [14] or isolated muscle
preparations [6,13]. Similarly, the naturally occurring thermo-
lysin inhibitor, phosphoramidon, has been found to have only
marginal e⁄cacy in inhibiting BoNT/B activity [13,14].
Using phosphoramidon as a template, we recently designed
and synthesized structural analogs in which the dipeptide Leu-
Trp of phosphoramidon was replaced by Phe-Glu: amino
acids that are present at the BoNT/B cleavage site of synap-
tobrevin-2 [15]. In addition, the rhamnose ring of phosphor-
amidon was replaced by a methyl, ethyl or a phenyl group in
di¡erent analogs. When tested on [Pya88] S 39^88, only the
phenyl derivative was found to have appreciable activity.
From these results, the minimal requirement for e⁄cacy
against BoNT/B LC appeared to be a pair of aromatic rings
£anking a central polarizable group oriented to interact with
the active site zinc [13]. Molecular modeling studies with met-
alloproteases of known active site structure (e.g. Pseudomonas
aeruginosa elastase) suggest that the zinc binding moiety in
ICD 1578 may be the carbonyl oxygen situated between the
phenyl and isocoumarin rings, the ketone oxygen in position 1
of isocoumarin or both (Fig. 1). In addition to the zinc bind-
ing group, ICD 1578 also has several other oxygens and two
nitrogens that can participate in hydrogen bonding, thus sta-
bilizing the molecule in the active site. From the energy mini-
mized conformation of ICD 1578, the length of the molecule
is V17 Aî . This is consistent with the relatively large active
site for serotype A recently reported from X-ray crystallogra-
phy data [18].
Although originally designed as a human leukocyte elastase
inhibitor, ICD 1578 conformed to the general criteria for ac-
tivity against BoNT/B LC and was therefore selected for de-
tailed examination. This compound was found to be su⁄-
ciently potent to be considered as a lead candidate for
further drug development. Discovery of therapeutic agents
for BoNT intoxication will be di⁄cult since, in addition to
the customary safety and e⁄cacy issues, the drug must be able
to penetrate biological membranes and reside in the nerve
terminal for as long as BoNT LC remains active. This study
represents the ¢rst step to that eventual goal.
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